Fragile X syndrome (FXS) is the most common form of inherited mental retardation and is caused by the functional loss of the Fragile X Mental Retardation Protein (FMRP). The estimated prevalence of FXS is 1:2500 males and 1:5000 females. FMRP is an RNA binding protein that is highly expressed in the brain, particularly at the synapse. FMRP is involved in mRNA transport and in the translational regulation of several neuronal mRNAs. The current model is that FMRP binds to specific sequences or structural motifs in mRNAs at the synapse and suppresses their translation. However, the precise mechanism of translational repression by FMRP is unknown. To determine the role of FMRP in FXS and elucidate the mechanism of how FMRP represses translation, we used the Drosophila model system, as flies lacking FMRP exhibit phenotypes observed in FXS. First, we showed with in vitro translation assays that FMRP represses translation of a Renilla luciferase reporter mRNA that does not have G-quadruplex or a pseudoknot forming sequence, which are the previously proposed FMRP-binding elements. Mutational analysis then revealed that the KH1 and RGG domains of FMRP are important for translation repression. Additionally, we developed a fluorescence-based, quantitative assay to monitor the binding of FMRP to the 80S ribosome. We found that FMRP binds with high affinity (KD = 20 ± 3 nM) to the Drosophila 80S ribosome near the 60S large ribosomal subunit protein L5 and this interaction was mRNA- independent. Finally, a cryo-electron microscopic reconstruction of the 80S ribosome·FMRP complex showed that FMRP binds within the inter-subunit space of the ribosomes such that it would block the binding regions of tRNA and translation elongation factors on the ribosome. These findings suggest a novel mechanism in which the binding of FMRP to the ribosome inhibits translation by blocking the docking of essential components of the translational machinery to the ribosome. These studies provide insight into the mechanism of translational control by FMRP and may help in identifying potential therapeutic approaches for treating FXS